Informace o publikaci

Target-Specific Magnetic Resonance Imaging of Human Prostate Adenocarcinoma Using NaDyF4-NaGdF4 Core Shell Nanoparticles

Autoři

DASH A. BLASIAK B. TOMANEK Boguslaw LATTA Peter VAN VEGGEL FCJM.

Rok publikování 2021
Druh Článek v odborném periodiku
Časopis / Zdroj ACS APPLIED MATERIALS & INTERFACES
Fakulta / Pracoviště MU

Středoevropský technologický institut

Citace
www https://pubs.acs.org/doi/10.1021/acsami.0c19273
Doi http://dx.doi.org/10.1021/acsami.0c19273
Klíčová slova anti-PSMA; MRI; relaxivity; nanoparticle; paramagnetic; dysprosium; gadlinium; EPR
Popis We illustrate the development of NaDyF4-NaGdF4 core-shell nanoparticles (NPs) for targeting prostate cancer cells using a preclinical 9.4 T magnetic resonance imaging (MRI) of live animals. The NPs composed of paramagnetic Dy3+ and Gd3+ (T-2- and T-1-contrast agents, respectively) demonstrate proton relaxivities of r(1) = 20.2 mM(-1) s(-1) and r(2) = 32.3 mM(-1) s(-1) at clinical 3 T and r(1) = 9.4 mM(-1) s(-1) and r(2) = 144.7 mM(-1) s(-1) at preclinical 9.4 T. The corresponding relaxivity values per NP are r(1) = 19.4 x 105 mM(NP)(-1) s(-1) and r(2) = 33.0 x 10(5) mMNP(-1) s(-1) at 3 T and r(1) = 9.0 x 105 mM(NP)(-1) s(-1) and r(2) = 147.0 x 10(5) mM(NP)(-1) s(-1) at 9.4 T. In vivo active targeting of human prostate tumors grown in nude mice revealed docking of anti-prostate-specific membrane antigen (PSMA) antibody-tagged NPs at tumor sites post-24 h of their intravenous injection. On the other hand, in vivo passive targeting showed preferential accumulation of NPs at tumor sites only within 2 h of their injection, ascribed to the enhanced permeation and retention effect of the tumor. A biodistribution study employing the harvested organs of mice, post-24 h injection of NPs, quantified active targeting as nearly twice as efficient as passive targeting. These outcomes provide potential opportunities for noninvasive diagnosis using NaDyF4-NaGdF4 core-shell NPs for target-specific MRI.
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info